Does Dabigatran Etexilate Interact with Pretomanid?
CDI records a unknown classification for Dabigatran Etexilate and Pretomanid. The stored summary is: P-gp substrate. In vitro studies suggest pretomanid may inhibit P-gp, potentially increasing dabigatran etexilate exposure. Clinical impact unknown; monitor for adverse reactions. The mechanism involves potential p-gp transporter inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Unknown
- Pretomanid Class
- Antimycobacterial
- Management
- Consult your pharmacist
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Potential P-gp transporter inhibition
What To Tell Your Doctor or Pharmacist
If you are taking Dabigatran Etexilate and your doctor is considering prescribing Pretomanid (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Never stop or change either medication without first consulting your healthcare provider